Abemaciclib

Abemaciclib (trade names Verzenio, Verzenios and Ramiven) is a drug for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.[1] It was designated as a breakthrough therapy for breast cancer by the U.S. Food and Drug Administration (FDA) in October 2015.[2] On 28 September 2017, it was approved for use in the United States by the FDA for the treatment of certain breast ... [wikipedia]